Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1621 1625 1629 1652
This examiner grants 81% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18279290 | INDOLE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Final Rejection | Mindset Pharma Inc. |
| 18265337 | Compound And Organic Light Emitting Device Comprising The Same | Non-Final OA | LG Chem, Ltd. |
| 18279903 | PROCESS FOR PREPARING A MELAMINE CONDENSATION PRODUCT | Final Rejection | BASF SE |
| 18790038 | COMPOSITIONS AND METHODS FOR REDUCING TACTILE DYSFUNCTION, ANXIETY, AND SOCIAL IMPAIRMENT | Non-Final OA | President and Fellows of Harvard College |
| 18781405 | METAL-ASSISTED DELAYED FLUORESCENT EMITTERS CONTAINING TRIDENTATE LIGANDS | Non-Final OA | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY |
| 18843651 | METHODS OF TREATING CANCER WITH IAP ANTAGONIST COMPOUNDS AND COMBINATION THERAPIES | Non-Final OA | Board of Regents, The University of Texas System |
| 18716052 | GLUCOCORTICOID RECEPTOR BLOCKADE WITH MIFEPRISTONE TO SENSITIZE PANCREATIC CANCER TO IMMUNOTHERAPY | Non-Final OA | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 18829547 | METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS | Non-Final OA | Gilead Sciences, Inc. |
| 18839131 | SMALL MOLECULES TARGETTING EIF3E TO INHIBIT TUMOR GROWTH PROGRESSION, AND METASTASIS | Non-Final OA | The Regents of the University of Colorado, A Body Corporate |
| 18719945 | AQUEOUS COSMETIC COMPOSITION COMPRISING VANILLIN OR ONE OF ITS DERIVATIVES, A SPECIFIC SEQUESTERING AGENT, AND POSSIBLY AT LEAST ONE ADDITIONAL ANTIMICROBIAL | Non-Final OA | L'OREAL |
| 18573785 | COMPOSITION FOR SUPPRESSING MUSCLE DAMAGE | Final Rejection | OTSUKA PHARMACEUTICAL CO., LTD. |
| 18841455 | NOVEL S1P1 RECEPTOR AGONIST, CRYSTALLINE SALTS, PROCESSES FOR PREPARING, AND USES RELATED THERETO | Non-Final OA | Arena Pharmaceuticals, Inc. |
| 18716131 | DIAMINOBUTOXY-SUBSTITUTED ISOFLAVONOIDS AS MITOCHONDRIAL COMPLEX I INHIBITORS FOR CANCER TREATMENT | Final Rejection | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION |
| 18293923 | INTEGRATED PROCESS FOR 5-(METHOXYCARBONYL)FURAN-2-CARBOXYLIC ACID (MCFC) | Final Rejection | Eastman Chemical Company |
| 18695585 | METHOD FOR PRODUCING ALKYLFURANCARBOXYLIC ACID ESTER | Non-Final OA | Mitsubishi Gas Chemical Company, Inc. |
| 18171735 | Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer | Non-Final OA | ASTRAZENECA AB |
| 17919650 | TARGETING THE PALMOTYLATION/DEPALMOTYLATION CYCLE TO TREAT INFLAMMATORY DISEASES | Final Rejection | CORNELL UNIVERSITY |
| 18792897 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | Non-Final OA | UNIVERSAL DISPLAY CORPORATION |
| 18812693 | DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS AND USES THEREOF | Non-Final OA | The United States of America,as represented by the Secretary,Department of Health and Human Services |
| 18544186 | CATALYST, APPLICATION THEREOF, AND METHOD FOR PREPARING 2,5-FURANEDICARBOXYLIC ACID BY CATALYZING 5-HYDROMETHYLFURFURAL IN BASE-FREE CONDITION | Final Rejection | Xiamen University |
| 18635402 | INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) | Non-Final OA | MEDIC Life Sciences Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy